Given your previous interest in following Chromadex Corp (OTCQX: CDXC), I wanted to alert you to an article published today in The Boston Globe which highlighted the launch of a new daily supplement called “BASISTM ” by Elysium Health. BASISTM is characterized as an advanced daily supplement designed to target metabolic repair and optimization.
From Elysium’s press release issued today: “A daily product for metabolic health, BASISTM contains two novel compounds. The first, nicotinamide riboside, is a precursor of the critical coenzyme NAD+, which is involved in metabolic processes such as energy production, DNA repair, cellular detoxification, the inflammatory response, and protein folding. The second component of BASISTM is a new polyphenol compound pterostilbene, which, like the NAD+ precursor, promotes metabolic health. Both compounds have been validated in numerous laboratories and been shown to improve metabolic health in scientific studies.”
The two active ingredients in BASISTM are both proprietary ingredients from ChromaDex: NIAGEN™ nicotinamide riboside and pTeroPure™ pterostilbene.
Elysium was co-founded by the renowned MIT researcher Dr. Leonard Guarente and Eric Marcotulli, a former partner at Silicon Valley-based Sequoia Capital. To support Elysium Health's business structure and mission, they have structured a scientific advisory board composed of more than 30 of the world's leading industry innovators, scientific researchers and clinicians, including five Nobel laureates.
